Insights into antibody-drug conjugates: Bioanalysis and biomeasures in discovery

Bioanalysis

Volumn 5, Issue 9, 2013, Pages 985-987

  Clark, Tracey ^a   Han, Xiaogang ^a   King, Lindsay ^a   Barletta, Frank ^a  

^a PFIZER INC   (United States)

Author keywords

biomeasures; discovery biotherapeutics; flow cytometry; ligand binding assay

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

DRUG DISPOSITION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IC 50; INTERNALIZATION; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTEIN EXPRESSION; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; IMMUNOCONJUGATES; LIGANDS; MASS SPECTROMETRY;

EID: 84877256857     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.65     Document Type: Review

References (15)

1. Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6), 677-700 (2011).
2. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6), 1125-1140 (2010).
3. Stephan JP, Chan P, Lee C et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19, 1673-1683 (2008).
4. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226 (2013).
5. Xu K, Liu L, Saad OM et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary LC-MS. Anal. Biochem. 412, 56-66 (2011).
6. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody conjugates. Nat. Biotechnol. 30, 184-189 (2012).
7. Teicher B, Chari R. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17(20), 6389-6397 (2012).
8. Van Der Graaf P, Benson N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 28(7), 1460-1464 (2011).
9. Maguire JJ, Kuc RE, Davenport AP. Radioligand binding assays and their analysis. In: Methods in Molecular Biology (Volume 897). Springer Science+Business Media, Berlin, Germany, 31-77 (2011).
10. Roskos LK, Schneider A, Vainshtein I et al. PK-PD modeling of protein drugs: implications in assay development. Bioanalysis 3(6), 659-675 (2011).
11. Wang L, Abbasi F, Gaigalas AK, Vogt RF, Marti GE. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells. Cytometry B Clin. Cytom. 70(6), 410-415 (2006).
12. Gratama JW, D'hautcourt JL, Mandy F et al. Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis. Cytometry 33(2), 166-178 (1998).
13. Sorkin A, Duex JE. Quantitative analysis of endocytosis and turnover of epidermal growth factor (EGF) and EGF receptor. Curr. Protoc. Cell Biol. Chapter 15, Unit 15.14 (2010).
14. Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res. 16(3), 888-897 (2010).
15. Sutherland MS, Sanderson RJ, Gordon KA et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281(15), 10540-10547 (2006).